Yoo, Yeong-Min, Kim, Kyung-Hoon · The Korean journal of pain · 2024 · DOI
Quick Summary
This article explains 'nociplastic pain'—a type of chronic pain that occurs when the nervous system becomes overly sensitive to pain signals, even when there is no obvious tissue damage or nerve injury. People with ME/CFS, fibromyalgia, and similar conditions often experience this kind of pain. The article describes how doctors can recognize nociplastic pain and groups it with other conditions that share this same underlying mechanism of nervous system sensitivity.
Why It Matters
Recognizing nociplastic pain as a legitimate neurobiological mechanism validates the experience of ME/CFS patients whose pain often lacks visible tissue damage. This framework helps clinicians move beyond the assumption that 'no lesion means no real pain,' potentially improving diagnosis, treatment strategies, and patient acceptance in healthcare settings.
Observed Findings
Eight specific disorders are associated with central sensitization mechanisms: restless leg syndrome, chronic fatigue syndrome, fibromyalgia, temporomandibular disorder, migraine or tension headache, irritable bowel syndrome, multiple chemical sensitivities, and whiplash injury.
Nociplastic pain can present with evoked pain hypersensitivity, allodynia (pain from non-painful stimuli), and after-sensation without clear nociceptive or neuropathic tissue pathology.
Common comorbidities in nociplastic pain conditions include sleep disturbance, fatigue, cognitive problems, and hypersensitivity of special senses (e.g., light, sound).
Three levels of diagnostic certainty are proposed: possible, probable, and definitive (not yet determined).
Inferred Conclusions
Nociplastic pain represents a unified neurobiological mechanism involving central sensitization that explains chronic pain in multiple syndromes previously classified as 'functional' or psychosomatic.
Both sensory components (hypersensitivity, allodynia) and emotional/psychiatric components (anxiety, depression, sleep disturbance) are genuine aspects of nociplastic pain, not separable causes and effects.
Development of definitive diagnostic criteria and better understanding of central sensitization mechanisms are needed to advance nociplastic pain diagnosis and treatment.
Remaining Questions
What specific neurobiological mechanisms underlie the transition from acute to persistent central sensitization in ME/CFS and related conditions?
What This Study Does Not Prove
This editorial does not present new experimental data proving that central sensitization causes ME/CFS or other conditions; it reviews existing concepts and diagnostic frameworks. It does not establish causality between emotional comorbidities and pain—only their frequent co-occurrence. The article also does not establish definitive diagnostic criteria, leaving clinical diagnosis somewhat subjective.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.
Can nociplastic pain be effectively treated, and if so, which therapeutic approaches (pharmacological, behavioral, neuromodulation) show the greatest promise?
How should healthcare systems implement nociplastic pain diagnostic criteria to improve patient recognition and appropriate clinical management?
Do nociplastic pain syndromes represent distinct disorders or variations of a single central sensitization spectrum?